Regeneron’s Melanoma Drug Crumbles Against Keytruda in Phase 3 Trial

Regeneron’s fianlimab + Libtayo combo showed 11.5 months PFS vs Keytruda’s 6.4 months in Phase 3 melanoma trial — but missed statistical significance. Analysts are “shaking heads” after the setback.